DSpace DSpace UPC
 Català   Castellano   English  

E-prints UPC >
Altres >
Enviament des de DRAC >

Empreu aquest identificador per citar o enllaçar aquest ítem: http://hdl.handle.net/2117/8480

Ítem no disponible en accés obert per política de l'editorial

Arxiu Descripció MidaFormat
Interruptions_antiretroviral.pdf280,68 kBAdobe PDF Accés restringit

Citació: Muñoz, J. [et al.]. Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?. "Journal of neurovirology", Juny 2010, vol. 16, núm. 3, p. 208-218.
Títol: Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
Autor: Clotet, Bonaventura; Garolera, Maite; Muñoz Moreno, Jose A.; Fumaz, Carmina R.; Prats, Anna; Ferrer, Maria J.; Negredo, Eugènia; Pérez Álvarez, Nuria Veure Producció científica UPC; Molto, Jose; Gómez Melis, Guadalupe Veure Producció científica UPC
Data: jun-2010
Tipus de document: Article
Resum: Because interruptions of antiretroviral treatment may entail clinical risks for human immunodeficiency virus (HIV)-infected individuals, we investigated their impact on neurocognitive functioning. Cross-sectional study was carried out, comparing HIV-infected persons who had interrupted antiretroviral therapy in the past (interruption group, IG) with persons who had never discontinued therapy (noninterruption group, NIG). Interruption was defined as the discontinuation of highly active antiretroviral therapy (HAART) for more than 15 days after previous treatment of at least 15 days. All the participants were on therapy. Demographic, clinical, and neurocognitive variables were assessed. The primary end point was the percentage of people with neurocognitive impairment. The score in different neurocognitive domains was a secondary end point. A total of 83 subjects participated in the study (IG: n = 27; NIG: n = 56). Demographic and clinical characteristics were balanced between the groups, except for years since HIV diagnosis (IG, 13.8; NIG, 10.2 [P = .003]). The percentage of people with neurocognitive impairment was significantly higher in the IG group (IG, 59.25%; NIG, 33.92% [P = 0.02]). As for scores in neurocognitive domains, individuals in the IG showed worse neurocognitive functioning, and significant differences in attention/working memory and information processing speed were found. The adjusted analysis supported the unadjusted analysis. In this study, a higher prevalence of neurocognitive impairment was detected in HIV-infected persons who had interrupted antiretroviral therapy in the past. Additionally, neurocognitive functioning was observed to be more impaired in the same individuals. Further studies should examine the potential negative effects of antiretroviral therapy interruptions on neurocognitive functioning.
ISSN: 1355-0284
URI: http://hdl.handle.net/2117/8480
DOI: 10.3109/13550281003767710
Versió de l'editor: http://www.ncbi.nlm.nih.gov/pubmed/20450380
Apareix a les col·leccions:GREMA - Grup de Recerca en Estadística Matemàtica i les seves Aplicacions. Articles de revista
Departament d'Estadística i Investigació Operativa. Articles de revista
Altres. Enviament des de DRAC
Comparteix:


Stats Mostra les estadístiques d'aquest ítem

SFX Query

Tots els drets reservats. Aquesta obra està protegida pels drets de propietat intel·lectual i industrial corresponents. Sense perjudici de les exempcions legals existents, queda prohibida la seva reproducció, distribució, comunicació pública o transformació sense l'autorització del titular dels drets.

Per a qualsevol ús que se'n vulgui fer no previst a la llei, dirigiu-vos a: sepi.bupc@upc.edu

 

Valid XHTML 1.0! Programari DSpace Copyright © 2002-2004 MIT and Hewlett-Packard Comentaris
Universitat Politècnica de Catalunya. Servei de Biblioteques, Publicacions i Arxius